SMAD1 and diabetic kidney disease: Another study from our research group found that sEVs derived from ADSCs improved the DKD patients’ symptoms through inhibiting SMAD family member 1 (Smad1)/mechanistic target of rapamycin (mTOR) signaling pathway by enhancing miR-486 expression in podocytes (Jin et al., 2019).